The direction of an asset coming out of discovery is the first key business decision organizations make toward ensuring that the asset will be differentiated and value-creating at launch. Oncology drugmakers today can expect to mount a sequence of indication launches over the lifecycle of their asset. As they do so, patients benefit from additional treatment options, and the research involved advances the understanding of these diseases. Yet, having multiple opportunities also tasks executives and researchers to set priorities and craft a well-defined approach to launch sequencing that is — at once —farsighted and sufficiently practical to leverage current marketplace opportunities.
But markets are changing at warp speed. There is a need to be more asset-focused and forward-looking when evaluating indication opportunities. More traditional methods of assessing indication opportunities are not forward-looking — nor are they asset-focused — and thus risk missing the mark.
With all that said, strategic decision-making can be improved by modest investments in developing prioritization criteria that are more specific to the asset and forward-looking.
This webinar will introduce a new and robust framework for indication prioritization that has resulted in more balanced and actionable assessments of individual indications by focusing not only on feasibility, but also on post-launch differentiation and value creation. Case studies will illustrate how this change in approach has improved decision-making and higher corporate valuations with less risk.
Register today to explore the different considerations for making better strategic decisions about indication prioritization.
Waynne Waterfield, Managing Director, Commercial Advisory, Syneos Health
Mr. Waterfield has over 20 years of experience working as an advisor to the biopharmaceutical industry. His consulting experience spans discovery to end of life cycle, with a focus on early stage commercialization strategy development — indication prioritization, product/portfolio strategy, commercial model design, distribution strategy, RoW entry and life cycle. Through his consulting career Mr. Waterfield has worked across clinical and commercial organizations to help shape development and commercialization strategy for numerous products in CNS, cardiology, CKD, oncology, endocrinology, infectious disease and pain.
Mr. Waterfield began his career and spent over 15 years in the pharmaceutical industry, where he held a range of executive level sales, market access and marketing positions. After his career in pharma, he became a member of the executive leadership team that successfully started-up and sold a company focusing on point-of-purchase consumer advertising for the pharmaceutical industry. For the last 20+ years he has worked as an advisor to multiple biopharmaceutical companies on early stage commercialization.
Mr. Waterfield earned an MBA with honors from the Northeastern D’Amore-McKim Graduate School of Business, a certificate in managerial finance and accounting from the University of Michigan and a BA in government and economics from Hamilton College
Paul Borron, M.Sc., Ph.D., Senior Engagement Manager, Commercial Advisory Group, Consulting, Syneos Health
Paul has served the pharmaceutical and biotech industry for over 20 years while in scientific strategy positions at small biotech start-ups. as well as in the CRO industry. He has been involved in a wide span of indications, both in preclinical and clinical research, including rare and pediatric diseases as well as medical devices.
Before joining Syneos Health Consulting, Paul worked in clinical and commercial strategy within several CRO industry over the course of the past 10 years. Prior to this experience, he was a Senior Scientist and NIH grant writer and reviewer while working at several small biotech companies in early discovery. This experience involved a wide span of activities from writing and publishing a patent to discovering new indications for early stage, preclinical assets as well as translational research.
Paul earned a bachelor’s degree in microbiology at the University of Western Ontario, a master’s degree in immunology at the University of Toronto and a doctorate in biochemistry at the University of Western Ontario. Paul also trained for five years as a post-doctoral fellow in the department of Cell Biology at Duke University.
Naveen Murthy, Sr. Managing Director, Commercial Advisory Group, Consulting, Syneos Health
Naveen Murthy brings nearly twenty five years in biopharma consulting, as well as experience in the biotechnology industry and a strong marketing, financial, and strategy background to his work at Syneos. Naveen leads the Product Development Strategy group within Syneos Consulting.
William Tam, Engagement Manager, Commercial Advisory Group, Consulting, Syneos Health
William joined Syneos Health in 2017 and has over 10 years of experience in the biopharma industry. His experience spans multiple therapeutic areas and along the entire product lifecycle. As a member of the Product Development Group at Syneos Health Consulting, William helps clients capture the full value of their product assets.
Who Should Attend?
Biopharma professionals with responsibilities in:
- Business Development
- Competitive/Business Intelligence
- Managed Markets/Care Strategy
- Market Access/Pricing
- Market Research
- New Product Planning
- Portfolio/Pipeline/Brand/Lifecycle Management
- Product Development/Management
- Research and Development
What You Will Learn
In this webinar, the speaker will:
- Discuss current best practices for indication prioritization and common pitfalls
- Introduce new clinical evaluation dimensions to improve assessments of clinical feasibility
- Define ways of working across Commercial, R&D and RWE stakeholders to ensure appropriate assumptions relating to clinical strategies and plans are developed
Syneos Health® (Nasdaq: SYNH) is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. We lead with a product development mindset, strategically blending clinical development, medical affairs, and commercial capabilities to address modern market realities.
Together we share insights, use the latest technologies, and apply advanced business practices to speed our customers’ delivery of important therapies to patients. We support a diverse, equitable and inclusive culture.